ASCO GU 2020: VEGF tyrosine kinase inhibitors as second-line treatment after immunotherapy for advanced kidney cancer
A retrospective analysis of data from the International Metastatic Renal [...]
A retrospective analysis of data from the International Metastatic Renal [...]
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]
Results from a recent phase 2 clinical trial of ilixadencel [...]
The treatment options for metastatic renal cell carcinoma (RCC) have [...]
This paper reviews the use of stereotactic body radiotherapy (SBRT) [...]
A recent study published in European Urology Oncology this month [...]
Two recent studies have looked at the effect of stereotactic [...]
Interim results from an ongoing clinical trial of lenvatinib and [...]
Two small studies looked at the addition of a type [...]
This interview with Dr Monty Pal, Associate Professor from the [...]